FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077372015> ?p ?o ?g. }

• W2077372015 endingPage "6" @default.
• W2077372015 startingPage "8051" @default.
• W2077372015 abstract "Axillary lymph node involvement in breast cancer is a marker of recurrence risk. Despite aggressive adjuvant therapy, recurrence in patients with four or more involved lymph nodes approaches 50% at 5 years from diagnosis. Markers that can distinguish those likely to relapse from those likely to be cured are needed to tailor therapy and provide accurate prognostic information to patients. Although most work in this area has focused on tumor characteristics, we hypothesized that the host environment might also play a role in determining risk of relapse. We hypothesized that host inflammatory response, mediated in part by production of interleukin-6 (IL-6), might play a role in the elimination of microscopic residual tumor. Polymorphisms in the IL-6 promoter region appear to modulate serum levels of the cytokine via regulation of gene transcription. A single nucleotide polymorphism involving substitution of cytosine for guanine at position -174 has been associated with reduced transcription and improved outcome in a variety of nonmalignant diseases, including coronary artery disease and several autoimmune conditions. Tumor necrosis factor (TNF) alpha is a proinflammatory cytokine that also plays a role in regulating IL-6 transcription. We hypothesized that polymorphisms in IL-6 (-174 G>C) or TNF-alpha (G-238 or G-308) might be associated with prognosis in a subset of patients with high-risk breast cancer. Genotyping was performed on DNA from stored stem cells in 80 breast cancer patients diagnosed with at least four positive axillary lymph nodes at diagnosis who underwent anthracycline-based adjuvant chemotherapy followed by high-dose multiagent chemotherapy with stem cell rescue. Cox proportional hazards models were used to estimate the effect of genotype and other known prognostic factors on disease-free and overall survival (DFS and OS, respectively). The presence of at least one C allele in the IL-6 promoter at position -174 was significantly associated with both DFS and OS compared with G/G homozygotes. After adjustment for estrogen receptor (ER) status, number of involved lymph nodes, and tumor size, those patients carrying the G/G genotype had a 2.1-fold increase in the rate of failure and a 2.6-fold increase in the rate of death compared with carriers of any C allele at a mean follow-up of 55 months. ER status modulated the effect of IL-6 polymorphism: both DFS and OS were most favorable in patients who were carriers of any C-allele (G/C or C/C) and had ER-positive tumors. The presence of either G/G genotype or an ER-negative tumor increased the hazard of failure [hazard ratio (HR), 2.6 and 3.2, respectively] and death (HR, 2.0 and 2.2, respectively). The combination of both G/G genotype and ER-negative tumor resulted in an additional increase in the hazard of failure (HR, 5.4; four-group comparison, P = 0.003) and death (HR, 6.2; four-group comparison, P = 0.001). TNF-alpha -308 and -238 polymorphisms were not associated with variation in DFS or OS in this cohort. The IL-6-174 promoter polymorphism is associated with clinical outcome in this cohort of node-positive breast cancer patients who received high-dose adjuvant therapy. IL-6 genotype modulated the effect of ER status on outcome. These results support the hypothesis that IL-6 may play an important role in the control of micrometastatic disease in breast cancer. Additional studies are needed to confirm these results and elucidate the mechanisms responsible for these differences." @default.
• W2077372015 created "2016-06-24" @default.
• W2077372015 creator A5004621453 @default.
• W2077372015 creator A5005537242 @default.
• W2077372015 creator A5012557553 @default.
• W2077372015 creator A5029801761 @default.
• W2077372015 creator A5035163601 @default.
• W2077372015 creator A5036113904 @default.
• W2077372015 creator A5038446967 @default.
• W2077372015 creator A5044395141 @default.
• W2077372015 creator A5052264374 @default.
• W2077372015 creator A5056176203 @default.
• W2077372015 date "2003-11-15" @default.
• W2077372015 modified "2023-10-06" @default.
• W2077372015 title "Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer." @default.
• W2077372015 cites W1495111481 @default.
• W2077372015 cites W1580788756 @default.
• W2077372015 cites W1644491781 @default.
• W2077372015 cites W1928213272 @default.
• W2077372015 cites W1993339376 @default.
• W2077372015 cites W1997452375 @default.
• W2077372015 cites W2003165120 @default.
• W2077372015 cites W2008548657 @default.
• W2077372015 cites W2012507063 @default.
• W2077372015 cites W2014830486 @default.
• W2077372015 cites W2041184642 @default.
• W2077372015 cites W2048912827 @default.
• W2077372015 cites W2054719874 @default.
• W2077372015 cites W2071235355 @default.
• W2077372015 cites W2089022749 @default.
• W2077372015 cites W2094924628 @default.
• W2077372015 cites W2101472630 @default.
• W2077372015 cites W2102157578 @default.
• W2077372015 cites W2109098920 @default.
• W2077372015 cites W2112331344 @default.
• W2077372015 cites W2155062006 @default.
• W2077372015 cites W48451113 @default.
• W2077372015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14633738" @default.
• W2077372015 hasPublicationYear "2003" @default.
• W2077372015 type Work @default.
• W2077372015 sameAs 2077372015 @default.
• W2077372015 citedByCount "40" @default.
• W2077372015 countsByYear W20773720152012 @default.
• W2077372015 countsByYear W20773720152013 @default.
• W2077372015 countsByYear W20773720152014 @default.
• W2077372015 countsByYear W20773720152015 @default.
• W2077372015 countsByYear W20773720152016 @default.
• W2077372015 countsByYear W20773720152017 @default.
• W2077372015 countsByYear W20773720152018 @default.
• W2077372015 countsByYear W20773720152020 @default.
• W2077372015 countsByYear W20773720152021 @default.
• W2077372015 countsByYear W20773720152023 @default.
• W2077372015 crossrefType "journal-article" @default.
• W2077372015 hasAuthorship W2077372015A5004621453 @default.
• W2077372015 hasAuthorship W2077372015A5005537242 @default.
• W2077372015 hasAuthorship W2077372015A5012557553 @default.
• W2077372015 hasAuthorship W2077372015A5029801761 @default.
• W2077372015 hasAuthorship W2077372015A5035163601 @default.
• W2077372015 hasAuthorship W2077372015A5036113904 @default.
• W2077372015 hasAuthorship W2077372015A5038446967 @default.
• W2077372015 hasAuthorship W2077372015A5044395141 @default.
• W2077372015 hasAuthorship W2077372015A5052264374 @default.
• W2077372015 hasAuthorship W2077372015A5056176203 @default.
• W2077372015 hasConcept C104317684 @default.
• W2077372015 hasConcept C121608353 @default.
• W2077372015 hasConcept C126322002 @default.
• W2077372015 hasConcept C135763542 @default.
• W2077372015 hasConcept C143998085 @default.
• W2077372015 hasConcept C153209595 @default.
• W2077372015 hasConcept C203014093 @default.
• W2077372015 hasConcept C2778690821 @default.
• W2077372015 hasConcept C502942594 @default.
• W2077372015 hasConcept C530470458 @default.
• W2077372015 hasConcept C54355233 @default.
• W2077372015 hasConcept C71924100 @default.
• W2077372015 hasConcept C86803240 @default.
• W2077372015 hasConceptScore W2077372015C104317684 @default.
• W2077372015 hasConceptScore W2077372015C121608353 @default.
• W2077372015 hasConceptScore W2077372015C126322002 @default.
• W2077372015 hasConceptScore W2077372015C135763542 @default.
• W2077372015 hasConceptScore W2077372015C143998085 @default.
• W2077372015 hasConceptScore W2077372015C153209595 @default.
• W2077372015 hasConceptScore W2077372015C203014093 @default.
• W2077372015 hasConceptScore W2077372015C2778690821 @default.
• W2077372015 hasConceptScore W2077372015C502942594 @default.
• W2077372015 hasConceptScore W2077372015C530470458 @default.
• W2077372015 hasConceptScore W2077372015C54355233 @default.
• W2077372015 hasConceptScore W2077372015C71924100 @default.
• W2077372015 hasConceptScore W2077372015C86803240 @default.
• W2077372015 hasIssue "22" @default.
• W2077372015 hasLocation W20773720151 @default.
• W2077372015 hasOpenAccess W2077372015 @default.
• W2077372015 hasPrimaryLocation W20773720151 @default.
• W2077372015 hasRelatedWork W1786110777 @default.
• W2077372015 hasRelatedWork W1984501713 @default.
• W2077372015 hasRelatedWork W2010276207 @default.
• W2077372015 hasRelatedWork W2085269092 @default.
• W2077372015 hasRelatedWork W2109466900 @default.

• next